Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.
Level 5 - mechanism / opinion, no new human data
Narrative expert review synthesizing literature without systematic search methodology.
PubMed 31647151 · doi:10.1111/jns.12335
What was done
Narrative review synthesizing evidence on the pathogenesis, incidence, clinical and pharmacogenetic risk factors, clinical phenotype, electrodiagnostic features, and management of platinum-induced peripheral neurotoxicity (PIPN).
What was found
The abstract provides no quantitative data or specific numerical estimates. It reports that oxaliplatin causes both acute and chronic non-length-dependent sensory neuronopathy, whereas cisplatin more frequently causes ototoxicity in children. Electrodiagnostic testing typically demonstrates diffusely reduced or abolished sensory action potentials. No established neuroprotective strategies currently exist, and evidence-based symptomatic therapy is limited to duloxetine based on a single phase III trial.
Why it matters
The paper outlines the distinct clinical phenotypes and diagnostic features of platinum neurotoxicity, highlighting a major therapeutic gap in neuroprotective interventions.
Limits
This is a narrative review without systematic search protocols, quality appraisal of included studies, or pooled quantitative analysis. No specific sample sizes, statistical risk factors, or quantitative efficacy metrics are provided in the abstract.
Cited by
- supports Platinum-containing cancer chemotherapy compounds are toxic to the ear, auditory neurons, and neurons throughout the body.